BioStock has published an article about Scandion Oncology. The focus is on the upcoming clinical Phase II trials that will enroll metastatic colorectal cancer patients that unfortunately no loger benefit from the standard chemotherapy treatment.
The article can be read here: https://www.biostock.se/2019/11/scandion-oncology-ready-for-phase-ii-with-sco-101/